EP05.01-032 The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC

PACIFIC trial has manifested a lower incidence of new brain metastasis in the durvalumab group than in the placebo group of patients with unresectable stage III NSCLC. Nevertheless, there are few studies mainly focusing on the effect of durvalumab on brain progression. Patients who receive radiotherapy (RT) may have adverse effects like symptomatic RP (radiation pneumonitis) which could be a life-threatening when combined with drug induced pneumonitis. Because many clinicians hesitate to start durvalumab after concurrent CCRT. The aim of this study is to evaluate the effects of durvalumab on brain metastasis and RP with real world data.